한국형 양극성 장애 약물치료 알고리듬 2022: 유지치료
Korean Medication Algorithm Project for Bipolar Disorder 2022: Maintenance Therapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives In this study, we investigated and organized the maintenance-treatment strategies for Bipolar I and II disorders outlined in The Korean Medication Algorithm Project for Bipolar disorder 2022 (KMAP-BP 2022). Methods The questionnaire sought to survey expert opinion on medication for bipolar disorders and was completed by a review committee consisting of 87 experienced Korean psychiatrists. It comprised 56 questions, and each question included various sub-items. The questionnaire for the maintenance treatments covered overall treatment strategies after acute mood episodes in bipolar I and II disorders, the choice of mood stabilizers and atypical antipsychotics and antidepressants, duration of medication, and treatment strategies for breakthrough symptoms. Results In the case of bipolar I disorder, mood stabilizer monotherapy, atypical antipsychoticsmonotherapy, and a combination of mood stabilizers and atypical antipsychotics were selectedas the first-line treatments. In maintenance management of bipolar II disorder, mood stabilizermonotherapy, atypical antipsychotics monotherapy, and combinations of mood stabilizers wereselected as the preferred first-line treatments. Conclusion There has been a growing body of evidence that atypical antipsychotics have agreater preference than observed in the previous KMAP-BP of 2018. Also, monotherapy ofmood stabilizers or atypical antipsychotics was more frequently selected in KMAP-BP 2022 thanin the KMAP-BP 2018.
Abstract
Objectives In this study, we investigated and organized the maintenance-treatment strategies for Bipolar I and II disorders outlined in The Korean Medication Algorithm Project for Bipolar disorder 2022 (KMAP-BP 2022). Methods The questionnaire sought to survey expert opinion on medication for bipolar disorders and was completed by a review committee consisting of 87 experienced Korean psychiatrists. It comprised 56 questions, and each question included various sub-items. The questionnaire for the maintenance treatments covered overall treatment strategies after acute mood episodes in bipolar I and II disorders, the choice of mood stabilizers and atypical antipsychotics and antidepressants, duration of medication, and treatment strategies for breakthrough symptoms. Results In the case of bipolar I disorder, mood stabilizer monotherapy, atypical antipsychoticsmonotherapy, and a combination of mood stabilizers and atypical antipsychotics were selectedas the first-line treatments. In maintenance management of bipolar II disorder, mood stabilizermonotherapy, atypical antipsychotics monotherapy, and combinations of mood stabilizers wereselected as the preferred first-line treatments. Conclusion There has been a growing body of evidence that atypical antipsychotics have agreater preference than observed in the previous KMAP-BP of 2018. Also, monotherapy ofmood stabilizers or atypical antipsychotics was more frequently selected in KMAP-BP 2022 thanin the KMAP-BP 2018.
참고문헌 (31)
- Treuer T, "Predicting the course and outcome of bipolar disorder : a review", Eur Psychiatry, 25, pp.328~333 (2010)
- Salloum IM, "Impact of substance abuse on the course and treatment of bipolar disorder", Bipolar Disord, 2(3 Pt 2), pp.269~280 (2000)
- MacQueen GM, "Bipolar II disorder: symptoms, course, and response to treatment", Psychiatr Serv, 52, pp.358~361 (2001)
- Goodwin GM, "What is a mood stabilizer?", Psychol Med, 37, pp.609~614 (2007)
- Schou M, "Bibliography on the biology and pharmacology of lithium. 5", Neuropsychobiology, 4, pp.40~64 (1978)
- McIntyre RS, "Lithium revisited", Can J Psychiatry, 46, pp.322~327 (2001)
- Bilo L, "Polycystic ovary syndrome in women using valproate : a review", Gynecol Endocrinol, 24, pp.562~570 (2008)
- Fountoulakis KN, "Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry", Eur Arch Psychiatry Clin Neurosci, 262(Suppl 1), pp.1~48 (2012)
- Jeong JH, "Korean medication algorithm for bipolar disorder 2014 : comparisons with other treatment guidelines", Neuropsychiatr Dis Treat, 11, pp.1561~1571 (2015)
- The Executive Committee of Korean Medication Algorithm Project for Bipolar Disorder, "The Korean medication guideline for bipolar disorder 2002" (2002), Choong-Ang-Moonwhasa
- 박원명, "양극성 장애의 한국형 약물치료 알고리듬", 대한정신약물학회지, 13(3), pp.205~221 (2002), 대한정신약물학회
- 김찬형, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅰ)：전반적 평가", 대한정신약물학회지, 16(3), pp.225~233 (2005), 대한정신약물학회
- 신영철, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅱ)：약물의 선택", 대한정신약물학회지, 16(4), pp.285~291 (2005), 대한정신약물학회
- 전덕인, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅲ)：치료반응과 내약성", 대한정신약물학회지, 16(4), pp.292~300 (2005), 대한정신약물학회
- 민경준, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(IV) : 삶의 질", 대한정신약물학회지, 16(5), pp.396~405 (2005), 대한정신약물학회
- Jon DI, "Revised Korean medication algorithm for bipolar disorder", World J Biol Psychiatry, 10(4 Pt 3), pp.846~855 (2009)
- Shin YC, "Korean medication algorithm for bipolar disorder : second revision", Asia Pac Psychiatry, 5, pp.301~308 (2013)
- Jon DI, "The Korean medication algorithm project for bipolar disorder (KMAP-BP):changes in preferred treatment strategies and medications over 16years and five editions", Bipolar Disord, 22, pp.461~471 (2020)
- Woo YS, "Korean medication algorithm project for bipolar disorder : third revision", Neuropsychiatr Dis Treat, 11, pp.493~506 (2015)
- Lish JD, "The National Depressive and Manic-depressive Association(DMDA)survey of bipolar members", J Affect Disord, 31, pp.281~294 (1994)
- Hlastala SA, "Bipolar depression : an underestimated treatment challenge", Depress Anxiety, 5, pp.73~83 (1997)
- Maj M, "Long-term outcome of lithium prophylaxis in bipolar disorder : a 5-year prospective study of 402 patients at a lithium clinic", Am J Psychiatry, 155, pp.30~35 (1998)
- 이정구, "한국형 양극성 장애 약물치료 알고리듬 2018 : 유지 치료", Mood and Emotion, 16(2), pp.86~95 (2018), 대한우울조울병학회
- Yatham LN, "Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
- Grunze H, "The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders:update 2012 on the long-term treatment of bipolar disorder", World J Biol Psychiatry, 14, pp.154~219 (2013)
- Goodwin GM, "Evidence-based guidelines for treating bipolar disorder:revised third edition recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 30, pp.495~553 (2016)
- Kanba S, "Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012", Psychiatry Clin Neurosci, 67, pp.285~300 (2013)
- Tohen M, "Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial", Am J Psychiatry, 162, pp.1281~1290 (2005)
- Tohen M, "Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone", Br J Psychiatry, 184, pp.337~345 (2004)
- Altamura AC, "Efficacy and tolerability of quetiapine in the treatment of bipolar disorder : preliminary evidence from a 12-month open-label study", J Affect Disord, 76, pp.267~271 (2003)
- McIntyre RS, "Aripiprazole for the maintenance treatment of bipolar disorder : a review of available evidence", Neuropsychiatr Dis Treat, 7, pp.319~323 (2011)